Search results
8 gru 2023 · Treatment of cancer-related pain has prospective evidentiary support for the use of medical cannabis. Although 3 large and well-designed randomized controlled trials investigated cannabis treatment of cancer-related pain, the evidence yielded only a grade D recommendation.
- A selective review of medical cannabis in cancer pain management
Anecdotal evidence suggests that medical cannabis has...
- Cannabis-based medicines and medical cannabis for adults with cancer pain
There is moderate-certainty evidence that oromucosal...
- Efficacy, tolerability and safety of cannabis-based medicines for ...
Very low quality evidence suggests that oromucosal...
- A selective review of medical cannabis in cancer pain management
24 cze 2022 · Very few well-designed, randomized controlled trials exist examining medical cannabis in patients with cancer pain. However, there has been increasing interest in cannabis use for cancer pain, given the lack of safety or tolerability of opioids and other analgesics (eg, renal impairment and nonsteroidal anti-inflammatory drugs, polypharmacy ...
5 sie 2017 · Anecdotal evidence suggests that medical cannabis has potential to effectively manage pain in this patient population. This review presents a selection of representative clinical studies, from small pilot studies conducted in 1975, to double-blind placebo-controlled trials conducted in 2014 that evaluated the efficacy of cannabinoid-based ...
5 cze 2023 · There is moderate-certainty evidence that oromucosal nabiximols and THC are ineffective in relieving moderate-to-severe opioid-refractory cancer pain. There is low-certainty evidence that nabilone is ineffective in reducing pain associated with (radio-) chemotherapy in people with head and neck canc ….
22 lut 2022 · An overview of Cochrane Reviews found the quantity and quality of evidence supporting the use of opioids for cancer pain to be low (Wiffen 2017). In clinical practice, however, most cancer patients will achieve adequate pain relief with opioids.
A systematic review was performed to identify all randomised controlled trials (RCTs) of cannabinoids compared with placebo or other active agents for the treatment of cancer-related pain in adults. A meta-analysis was performed to determine cannabinoid effectiveness and adverse effects, including dropouts.
Very low quality evidence suggests that oromucosal nabiximols and THC have no effect on pain, sleep problems and opioid consumption in patients with cancer pain with insufficient pain relief from opioids.
